Pacific Biosciences Of California (PACB) Free Cash Flow (2010 - 2026)

Pacific Biosciences Of California's Free Cash Flow history runs 17 years deep, the most recent figure standing at -$47.7 million for Q1 2026.

• On a quarterly basis, Free Cash Flow fell 5.04% year-over-year to -$47.7 million in Q1 2026; TTM through Mar 2026 was -$116.2 million, a 34.76% increase from a year earlier, with the FY2025 full-year figure at -$113.9 million, up 46.33% from the prior year.
• Free Cash Flow declined to -$47.7 million in Q1 2026 per PACB's latest filing, from -$19.9 million in the prior quarter.
• Across five years, Free Cash Flow topped out at -$18.6 million in Q3 2025 and bottomed at -$98.4 million in Q1 2023.
• The 5-year median for Free Cash Flow is -$55.7 million (2024), against an average of -$54.2 million.
• Across the five-year window, Free Cash Flow sank 273.72% in 2022 and soared 58.32% in 2025, its largest moves.
• Year by year, Free Cash Flow stood at -$65.5 million in 2022, then rose by 8.99% to -$59.6 million in 2023, then surged by 45.85% to -$32.3 million in 2024, then soared by 38.23% to -$19.9 million in 2025, then sank by 139.51% to -$47.7 million in 2026.
• Per Business Quant, the three latest PACB Free Cash Flow figures stand at -$47.7 million (Q1 2026), -$19.9 million (Q4 2025), and -$18.6 million (Q3 2025).